Investigational drug · Phase 3
divozilimab
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Neuromyelitis Optica Spectrum Disorders, Systemic Scleroderma.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "divozilimab"
First trial start
2022
Dec 12, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "divozilimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Neuromyelitis Optica Spectrum Disorders
- Systemic Scleroderma
Largest trials
Live from ClinicalTrials.gov: studies naming "divozilimab" as an intervention, largest first.
- Clinical Study of Divozilimab in Patients With Systemic SclerodermaPivotal-lookingActive, not recruiting
BiocadIndustry
NCT05726630 · 152 participants · Start Dec 26, 2022 · Primary completion Oct 1, 2024
Drug: Divozilimab; Placebo · For: Systemic Scleroderma
Sites: Chelyabinsk, Russia; Saint Petersburg, Russia · 3 sites in all
BiocadIndustry
NCT07136389 · 135 participants (planned) · Start Mar 27, 2025 · Primary completion Jan 1, 2026
Drug: BCD-256; BCD-256 and 3 more · For: Systemic Lupus Erthematosus
Sites: Saint Petersburg, Russia
- Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)Pivotal-lookingActive, not recruiting
BiocadIndustry
NCT05730699 · 105 participants (planned) · Start Dec 12, 2022 · Primary completion Jan 2025
Drug: divozilimab · For: Neuromyelitis Optica Spectrum Disorders
Sites: Barnaul, Russia; Chelyabinsk, Russia; Kemerovo, Russia · 19 sites in all
- An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCADPivotal-lookingCompleted
BiocadIndustry
NCT06987851 · 44 participants · Start Mar 22, 2022 · Primary completion May 16, 2024
Drug: Divozilimab · For: Multiple Sclerosis
Sites: Kirov, Russia; Krasnoyarsk, Russia; Moscow, Russia · 15 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Anti-CD20 monoclonal antibody therapies in relapsing multiple sclerosis: A systematic review and meta-analysis of randomised controlled trials.
Alatawi A, Al-Dhahi AS, Alatawi A, et al. · Mult Scler Relat Disord 2026
- The Efficacy and Safety of Divozilimab in Patient with Systemic Sclerosis: 48-Week Results of the Randomized Double-Blind Placebo-Controlled Phase III Clinical Study LIBERIUS.
Ananyeva LP, Starovoytova MN, Gaydukova IZ, et al. · Dokl Biochem Biophys 2026
- [Results of 4 years of therapy with divozilimab in patients with relapsing multiple sclerosis].
Boyko AN, Alifirova VM, Goncharova ZA, et al. · Zh Nevrol Psikhiatr Im S S Korsakova 2025
- [Comparing the efficacy of divozilimab and second-line treatments for relapsing-remitting multiple sclerosis in the Russian Federation: a systematic review and network meta-analysis].
Zakharova MN, Simaniv TO, Sapozhnikov KV, et al. · Zh Nevrol Psikhiatr Im S S Korsakova 2025
- [The first experience with the use of divozilimab in the treatment of multiple sclerosis patients in daily clinical practice].
Lebedev VM, Kuzminykh ED · Zh Nevrol Psikhiatr Im S S Korsakova 2024
- [Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS].
Boyko AN, Alifirova VM, Lukashevich IG, et al. · Zh Nevrol Psikhiatr Im S S Korsakova 2024
Also in development for Neuromyelitis Optica Spectrum Disorders
- GlucocorticoidsPhase 37 trials
Novartis · VEXAS Syndrome, ANCA Associated Vasculitis (AAV), Anti-Glomerular Basement Membrane Disease
- B001Phase 31 trial
Shanghai Jiaolian Drug Research and Development Co., Ltd · Neuromyelitis Optica Spectrum Disorders
- JYP0061Experimental Drug GroupPhase 22 trials
Guangzhou JOYO Pharma Co., Ltd · Moderate-to-severe Atopic Dermatitis, Neuromyelitis Optica Spectrum Disorders
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.